Quantification of asenapine and three metabolites in human plasma using liquid chromatography-tandem mass spectrometry with automated solid-phase extraction: application to a phase I clinical trial with asenapine in healthy male subjects

Biomed Chromatogr. 2012 Feb;26(2):156-65. doi: 10.1002/bmc.1640. Epub 2011 May 6.

Abstract

The development and validation of methods for determining concentrations of the antipsychotic drug asenapine (ASE) and three of its metabolites [N-desmethylasenapine (DMA), asenapine-N(+) -glucuronide (ASG) and 11-O-sulfate-asenapine (OSA)] in human plasma using LC-MS/MS with automated solid-phase extraction is described. The three assessment methods in human plasma were found to be acceptable for quantification in the ranges 0.0250-20.0 ng/mL (ASE), 0.0500-20.0 ng/mL (DMA and OSA) and 0.250-50.0 ng/mL (ASG).

Publication types

  • Clinical Trial, Phase I
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Chromatography, Liquid / methods*
  • Dibenzocycloheptenes
  • Double-Blind Method
  • Drug Stability
  • Heterocyclic Compounds, 4 or More Rings / blood*
  • Heterocyclic Compounds, 4 or More Rings / metabolism
  • Heterocyclic Compounds, 4 or More Rings / pharmacokinetics
  • Humans
  • Linear Models
  • Male
  • Middle Aged
  • Reference Standards
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Solid Phase Extraction / methods*
  • Tandem Mass Spectrometry / methods*

Substances

  • Dibenzocycloheptenes
  • Heterocyclic Compounds, 4 or More Rings
  • asenapine